{
    "name": "immune globulin IM (IGIM)",
    "comment": "Rx",
    "other_names": [
        "GamaSTAN",
        "IM Immune Globulins",
        "ISG",
        "GamaSTAN S/D"
    ],
    "classes": [
        "Immune Globulins"
    ],
    "source": "https://reference.medscape.com/drug/gamastan-s-d-immune-globulin-im-igim-343137",
    "pregnancy": {
        "common": [
            "There are no data with use in pregnant women to inform a drug-associated risk",
            "Animal reproduction studies have not been conducted",
            "Unknown if fetal harm may occur when administered to a pregnant woman or can affect reproduction capacity"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There is no information regarding presence of immunoglobulin IM in human milk, the effect on the breastfed infant, or the effects on milk production",
            "Consider the developmental and health benefits of breastfeeding along with the motherâ€™s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Thrombosis ",
                    "description": [
                        "Thrombosis may occur regardless of the route of administration",
                        "Risk factors include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity and cardiovascular risk factors",
                        "Thrombosis may occur in the absence of known risk factors",
                        "For patients at risk of thrombosis, administer at the minimum concentration available and at the minimum rate of infusion practicable",
                        "Ensure adequate hydration in patients before administration",
                        "Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Anaphylactic or severe systemic hypersensitivity reactions to immune globulin (human)",
                "IgA deficient patients with antibodies against IgA and a history of hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use with caution in patients with a history of prior systemic allergic reactions to human immunoglobulin preparations; do not perform skin test; misinterpretation of such tests can lead to withholding beneficial human immunoglobulin from a patient who is not actually allergic to this material",
                "Thrombosis may occur following treatment with immune globulin products (see Black Box Warnings)",
                "Inject IM only; do not administer IV owing to risk for serious reactions (eg, renal dysfunction/failure/hemolysis, transfusion-related acute lung injury [TRALI]); do not inject into a blood vessel",
                "Drug is made from human blood and may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent; drug is purified from human plasma obtained from healthy donors"
            ],
            "specific": [
                {
                    "type": "Drug interactions overview",
                    "description": [
                        "Antibodies in immunoglobulin IM may interfere with response to live virus vaccines (eg, measles, mumps, polio, rubella, and varicella); defer live vaccine administration for up to 6 months after administration"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "immune globulin IM (IGIM), axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "immune globulin IM (IGIM), brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "immune globulin IM (IGIM), ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "immune globulin IM (IGIM), idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "immune globulin IM (IGIM), lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "immune globulin IM (IGIM), tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "BCG vaccine live",
            "description": {
                "common": "immune globulin IM (IGIM) decreases effects of BCG vaccine live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efgartigimod alfa",
            "description": {
                "common": "efgartigimod alfa will decrease the level or effect of immune globulin IM (IGIM) by  receptor binding competition. Use Caution/Monitor. Coadministration of efgartigimod with medications that bind to the human neonatal Fc receptor may lower systemic exposures and effectiveness of such medications. Closely monitor for reduced effectiveness of medications that bind to the human neonatal Fc receptor. If long-term use of such medications is essential, consider discontinuing efgartigimod and using alternative therapies."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles (rubeola) vaccine",
            "description": {
                "common": "immune globulin IM (IGIM) decreases effects of measles (rubeola) vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles mumps and rubella vaccine, live",
            "description": {
                "common": "immune globulin IM (IGIM) decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles, mumps, rubella and varicella vaccine, live",
            "description": {
                "common": "immune globulin IM (IGIM) decreases effects of measles, mumps, rubella and varicella vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rubella vaccine",
            "description": {
                "common": "immune globulin IM (IGIM) decreases effects of rubella vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "smallpox (vaccinia) vaccine, live",
            "description": {
                "common": "immune globulin IM (IGIM) decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "varicella virus vaccine live",
            "description": {
                "common": "immune globulin IM (IGIM) decreases effects of varicella virus vaccine live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethotoin",
            "description": {
                "common": "ethotoin, immune globulin IM (IGIM). Mechanism: unknown. Minor/Significance Unknown. Risk of hypersensitivity myocarditis."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin, immune globulin IM (IGIM). Mechanism: unknown. Minor/Significance Unknown. Risk of hypersensitivity myocarditis."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin, immune globulin IM (IGIM). Mechanism: unknown. Minor/Significance Unknown. Risk of hypersensitivity myocarditis."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "protein a column",
            "description": {
                "common": "protein a column decreases levels of immune globulin IM (IGIM) by Other (see comment). Minor/Significance Unknown. \nComment: Since Prosorba binds IgG, it could theoretically interfere with the levels and/or effects of pharmacologic immune globulins."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Local pain and tenderness at injection site",
            "percent": null
        },
        {
            "name": "Anaphylactic reaction",
            "percent": null
        },
        {
            "name": "Angioedema",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Injection site pain",
            "percent": null
        },
        {
            "name": "Injection site inflammation",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "Pyrexia",
            "percent": null
        }
    ]
}